持续型红细胞生成素受体激活剂研究进展

Progress of continuous erythropoietin receptor activator

红细胞生成素(EPO)是机体在生理条件下以及失血后调控红细胞生成的主要生长刺激因子,是目前治疗由肾功能衰竭、慢性感染、获得性免疫缺陷综合征、肿瘤或其他原因引起的贫血病的特效临床药物之一。但由于其在人体内的血浆半衰期较短,需要频繁注射,给患者带来很大痛苦。因此,开发长效EPO一直是该领域的研究热点。持续型EPO受体激活剂(CERA)是新出现的一种第三代红细胞生成刺激剂(ESA)。与常规EPO不同,它具备较长的体内半衰期,可减少注射次数。本文阐述了CERA的由来,分子结构和生化特征,不良反应及其作为新型兴奋剂使用所引起的国际关注。

Erythropoietin（EPO） is a main growth factor that regulates the erythropoiesis under the physiological conditions and after blood loss.At present,it is one of the special effective clinical drugs for treating anemia due to renal failure,chronic infection,AIDS,tumor and some other causes.However,its short plasma half-life makes more frequent administration,which increases the burden and pain on patients.Therefore,development of long-acting agents is a hot.Continuous erythropoietin receptor activator（CERA） is a third-generation erythropoiesis-stimulating agents（ESA）.It has a largely prolonged plasma half-life and extended administration intervals,which are different from other ESAs.This review gives a detail demonstration about the development,molecular structure,biochemical characteristics and the most common adverse effects of CERA .